- Home
- » CME / CE Programs
- » Expert Practice Articles
- » A Practical Guide to the Management of Psoriatic Arthritis: Defining the Role of Dermatology Professionals
A Practical Guide to the Management of Psoriatic Arthritis: Defining the Role of Dermatology Professionals
Release date: November 2009
Expiration date: November 30, 2010
Estimated time to complete activity: 30 minutes
No longer available for CME credit
Sponsored by Curatio CME Institute
Support for this activity has been provided through educational grants from Amgen and Genentech.
Activity Overview
Psoriatic arthritis is an inflammatory joint condition that in some patients follows the development of psoriasis. Because of the association between these two conditions, the dermatologist plays a crucial role in the diagnosis, and often the management of, psoriatic arthritis. In this Expert Practice, Dr. Kenneth Gordon of the University of Chicago Pritzker School of Medicine and the NorthShore University HealthSystem discusses how dermatologists should approach the diagnosis and management of psoriatic arthritis. The role of the rheumatologist in the care of patients with psoriatic arthritis is also addressed.
Target Audience
This activity has been designed to meet the educational needs of dermatologists, dermatology residents and fellows, dermatology nurses, nurse practitioners, physician assistants, and other health care professionals involved in the care of patients with moderate to severe psoriasis.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Indicate signs and symptoms of psoriatic arthritis
- Identify patients with psoriasis and concomitant joint disease
- Describe treatment options for psoriasis and psoriatic arthritis
Faculty
Kenneth B. Gordon, MD
Clinical Associate Professor of Dermatology
University of Chicago Pritzker School of Medicine
Head, Division of Dermatology
NorthShore University HealthSystem
Chicago, Illinois
Accreditation Statement
Curatio CME Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation
Curatio CME Institute designates this educational activity for a maximum of 0.5 AMA PRA Category 1 Credit ™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Method of Participation
There are no fees for participating in this CME activity. To receive credit during the period November 2009 to November 30, 2010, participants must (1) read the learning objectives and disclosure statements, (2) study the educational activity, (3) complete the posttest, and (4) complete the activity evaluation form.
Media
The Internet was selected as the instructional format to accommodate the learning preferences of a significant portion of the target audience.
Disclosure
In accordance with the ACCME Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of everyone in a position to control content of an educational activity. A relevant financial relationship is a relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears below:
Kenneth B. Gordon, MD, has disclosed the following relevant financial relationships:
| Investigator/Consultant | Abbott, Amgen, Centocor Ortho Biotech |
Curatio CME Institute
Shari J. Dermer, PhD, Medical Director, has disclosed no relevant financial relationships.
Thomas Finnegan, PhD, Medical Writer, has disclosed no relevant financial relationships.
Jonathan S. Simmons, ELS, Managing Editor, has disclosed no relevant financial relationships.
Derek Warnick, CME Director, has disclosed no relevant financial relationships.
Disclaimer
The information presented at this activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician regarding diagnosis and treatment of a specific patient’s medical condition.
Unapproved Product Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Curatio CME Institute, Amgen, and Genentech, Inc. do not recommend the use of any agent outside the labeled indications.
The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Curatio CME Institute, Amgen, or Genentech, Inc. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
| Generic Name | Trade Name | Approved Use (if any) | Unapproved/ Investigational Use |
| Alefacept | Amevive | Indicated for patients with moderate to severe psoriasis who are candidates for systemic therapy or phototherapy | Treatment of psoriatic arthritis |
| Cyclosporine | Neoral | Indicated for prophylaxis of organ rejection in kidney, liver, and heart allogenic transplants; chronic rejection in patients previously treated with other immunosuppressive agents; severe active rheumatoid arthritis that does not adequately respond to methotrexate; severe and recalcitrant psoriasis that is not responsive to at least one systemic therapy or in patients where other systemic therapies are contraindicated or intolerable | Treatment of psoriatic arthritis |
| Leflunomide | Arava | Indicated for the treatment of active rheumatoid arthritis | Treatment of psoriatic arthritis |
| Methotrexate | Rheumatrex | Indicated for the treatment of gestational choriocarcinoma, chorioadenoma destrusens, and hydatidiform mole; maintenance therapy in combination with other chemotherapeutic agents; used alone or in combination with other anticancer agents in the treatment of breast cancer, epidermoid cancers of the head or neck, advanced mycosis fungoides, and lung cancer; in combination with other chemotherapeutic agents in the treatment of advanced stage non-Hodgkin’s lymphomas; treatment of severe, recalcitrant, disabling psoriasis; treatment of adults with severe and active rheumatoid arthritis or children with active polyarticular-course juvenile rheumatoid arthritis who are intolerant or unresponsive to frontline therapy | Treatment of psoriatic arthritis |
| Sulfasalazine | Azulfidine EN-tabs | Mild/moderate ulcerative colitis; prolongation of remission between acute attacks of ulcerative colitis; patients with rheumatoid arthritis with an inadequate response to nonsteroidal anti-inflammatory drugs (NSAIDs); pediatric patients with polyarticular-course juvenile rheumatoid arthritis who had an inadequate response to NSAIDs | Treatment of psoriatic arthritis |
Hardware/Software Requirements
- JavaScript-enabled Interner browser
Contact Information
PsoriasisTx.com
100 Campbell Boulevard
Suite 103
Exton, PA 19341
editor@psoriasistx.com
Policy on Privacy and Confidentiality
Curatio CME Institute makes every effort to protect the privacy of PsoriasisTx.com users; user information is used only to maintain records as required by the American Medical Association (AMA) and the ACCME.
Curatio CME Institute does not require individuals to register to use PsoriasisTx.com; registration is only required for physicians, health care professionals, and other users to participate in and receive CME/CE credit for accredited educational programs hosted on PsoriasisTx.com
Curatio CME Institute is required by the AMA and the ACCME (and occasionally by other accrediting organizations) to collect user information that will allow Curatio CME Institute to issue a CME/CE certificate. Curatio CME Institute is required to keep this information on file for up to 6 years. The information is stored in a secure database and used only to verify individual participation in a CME/CE activity and to reissue a certificate if a user's original certificate is lost or misplaced.
Information gathered through PsoriasisTx.com will not be released to any other company or organization for any purpose; this information remains confidential.
Curatio CME Institute uses Web site tracking software to determine how PsoriasisTx.com is used. This information helps Curatio CME Insitute determine the best strategies for improving PsoriasisTx.com and better meeting the needs of its users. This software does not identify individual users.
If you have any questions about PsoriasisTx.com or any Curatio CME Institute policies, you may contact us at info@psoriasistx.com.
Thank you for using PsoriasisTx.com.
